Louisiana BIO Board of Directors

 
TG8_5055-2.jpg

ISABELLA SLEDGE MD (BOARD CHAIR)

Isabella Sledge MD, MPH – is a Founder and the VP of Research and Development at Tides Medical, a biotechnology company focused on regenerative medicine. Dr. Sledge is an internist and health outcomes researcher who has focused her career on evidence development for emerging healthcare technologies.

Dr. Sledge received her medical degree from University of Maryland School of Medicine and holds a Masters in Public Health from the Harvard School of Public Health.

Unknown-2.jpeg

Joseph F. Lovett

Mr. Lovett is a Managing Director of Louisiana Funds (LF I & II), two early stage venture capital funds with $40 million under management based in Louisiana with offices in New Orleans and Baton Rouge. LF’s focus is on forming early stage companies primarily based on research at the major Louisiana research universities (LSU, Tulane and Louisiana Tech University) in the areas of biotechnology, life sciences, pharmaceuticals, medical devices, agri-technology, engineering, software, security and internet technologies.

To date LF I has started or invested in 13 companies primarily based upon research licensed from the major research universities in Louisiana with 11 licenses (8 from LSU, 1 from Tulane and 2 from Louisiana Tech). In addition to the investment from Louisiana Fund I, an additional $150,000,000 has been raised from 16 venture capital and mezzanine investors for the 13 companies in the LF I portfolio.  Louisiana Fund II has invested in 7 early stage companies in Florida, Louisiana, Texas and Colorado.

Mr. Lovett has spent his entire 47 year career in the life sciences industry starting with CR Bard, Mallinckrodt and Damon Biotech in increasingly responsible positions in sales, marketing and general management.

Dale+Pfost.jpg

Dale R. Pfost

Dale Pfost is a Partner of the London-based Advent Life Sciences, one of the leading venture capital funds in Europe. Dale has 25 years of experience as a life science entrepreneur and senior executive. He is currently also serving as the acting CEO of MicroBiome Therapeutics and on the board of Aura BioSciences, an ophthalmic cancer company.

Dale has been the CEO of five successful biotechnology companies, three of which became publically traded, with valuations of over $1 Billion. He was the founding CEO of Acuity Pharmaceuticals which had the first-ever clinical trial with an siRNA drug and undertook a reverse merger to form OPKO Health (NYSE: OPK). He was the founding CEO of Oxford GlycoSciences and Orchid BioSciences, both of which had IPOs in 1998 and 2000 respectively. His first company, started while he was in grad school, was acquired by SmithKline Beckman and produced the Biomek, a leading laboratory automation system.

Dale has led 22 financings raising over $300 million, has led the M&A of nine companies and served on 16 boards of directors of public, private and non-profit companies. He has been with Advent Life Sciences for eight years. He has PhD in Physics from Brown University and a BS in Physics from UC Santa Barbara. He works from his two home offices, one in Los Altos, California and the other in New Orleans.

 
Turner_Holly_2019_005_SYNC.jpg
SPP_8084-Jeanette_600x600.jpg
G_Davenport-color_headshot.jpg

HOLLY TURNER

Holly Jacques Turner is a Director for the Merck State Government Affairs and Policy Division.  In this role, Holly oversees all legislative and regulatory work for Merck in Louisiana, Oklahoma and Texas. 

Before joining Merck in 1997, Holly was the Director of Health Policy for Texas Lieutenant Governor Bob Bullock.

Jeanette Wieland

the senior director of bio business & strategy, having recently served from 2015-2018 as a financial operations manager with Ochsner Health System’s retail division and as a system-wide administrative finance fellow. From 2009 to 2015, she was executive vice president of CIC Wealth, a Washington, D.C. investment advisory firm. Weiland began her finance career with the wealth advisory team at Capital One and USB Financial Services in New Orleans from 2006 to 2009 as a Series 7 and 66 license holder.

Her strong background in healthcare finance, financial management and business development allows her to step into the new role with deep-seated knowledge of the health and business community in New Orleans.

As the senior director of Bio Business & Strategy, Weiland will spearhead efforts to attract, retain, and expand businesses and investment while spurring job creation in the BioInnovation cluster in New Orleans.

Weiland is a certified Lean Six Sigma Greenbelt and has served on the board of several local nonprofits, including her current board position on the New Orleans Garden District Association. She earned a bachelor of science degree in International Trade and Finance at Louisiana State University. Additionally, Weiland holds a Masters of Arts in Arts Administration and a masters of business administration from The University of New Orleans.

Gregory J. Davenport

Gregory J. Davenport, Ph.D., is currently President of Full Spectrum Omega, Inc., a Life Sciences Corporation developing phytocannabinoids to address unmet medical conditions and Principal & CEO of Davenport & Companies, LLC, a broad based professional management firm that provides value-added business solutions to various clients.

Known as a results oriented executive, Dr. Davenport has over 25 years of experience in building organizations and managing programs. Prior to joining Full Spectrum Omega, Inc., Dr. Davenport was a Vice President for a DC firm specializing in non-dilutive funding where he secured Federal contracts and in kind services for clients including a $21 million contact for a Virginia-based antibiotic company.

Throughout his career, Dr. Davenport has held various C-­‐level executive positions with biotech and life science companies including Tunnell Consulting (an employee-­‐owned company providing technical, organizational and operational consulting to Federal and Life Science clients), Dor Biopharma, Inc. (publicly traded biotech company), and Dynport Vaccine Company (previous subsidiary of CSC)) were he secured more than $350 M in non-­‐dilutive funding.

Dr. Davenport earned a Bachelor of Science degree from Dillard University in New Orleans, Louisiana, received his Ph.D. in Molecular Biology from Howard University in Washington, D.C., and performed postdoctoral studies at the University of Maryland Medical Center and George Washington University Medical Center. Dr. Davenport also serves on the advisory board the New Orleans BioInnovation Center, www.neworleansbio.com and the Mount St. Mary’s University Biotechnology & Management Program, www.msmary.edu.